GLP1R and type 2 diabetes mellitus: From the original cohort of 69,997 patients who underwent a primary gastric bypass or sleeve gastrectomy from January 1, 2007 until December 31, 2019 and 699,970 persons from the general population, 8659 patients from the surgical cohort with T2D and at least one drug as treatment, and 2879 non-surgical patients with T2D and GLP-1 agonist as part of treatment were identified.